Proposed bill would allow Marylanders to disclose nonapparent disabilities on their IDs
Eric's ID Law, or HB707, would require the Motor Vehicle Administration (MVA) to add a certain symbol to licenses, ID cards or moped permits indicating that the applicant has a nonapparent disability.
The idea was proposed by a Maryland family during an appearance on ABC's "The View," The Baltimore Banner reported.
The Carpenter-Grantham family had the idea after the 2020 murder of George Floyd which sparked protests across the nation.
"I realized that I have an African American son with an invisible disability," mother Linda Carpenter-Grantham said during the TV appearance.
The bill was introduced in the state Senate during the 2024 legislative session but missed a deadline in the House.
The proposed bill would require the MVA to establish public outreach programs to educate the public about the new symbols or notations. The MVA would work with disability advocates to design the symbols.
The MVA would be prohibited from sharing information about an applicant's disabilities.
The bill would also prevent the MVA from asking an applicant to provide proof of their disability or reject an application because the listed disability does not match other documents associated with the applicant.
Under the bill, the Maryland Police Training and Standards Commission and Department of State Police would have to immediately implement training for police interactions with those who have nonapparent disabilities noted on their IDs.
The bill will be the subject of a hearing on Feb. 13 at 1 p.m.
What is a nonapparent disability?
According to the proposed bill, a nonapparent disability is a health condition that is not immediately obvious or visible, this could include developmental or intellectual disabilities.
According to a study by the National Institutes of Health (NIH), common nonapparent disabilities are anxiety and depression, Alzheimer's, deafness, post-traumatic stress disorder (PTSD), attention-deficit hyperactivity disorder/attention deficit disorder (ADHD/ADD), and diabetes among others.
People with developmental disabilities are about seven times more likely to encounter law enforcement than neurotypical individuals, according to a 2001 study by the Department of Justice.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Cholesterol Isn't Just About Heart Health—It May Be the Missing Link In Alzheimer's, Says New Study
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." A new study suggests that there's a link between how well you move cholesterol to the neurons in your brain and Alzheimer's disease. This factor is connected to the APOE4 genetic variant, which significantly increases your risk of developing the disease. Here's what to know and what this means for Alzheimer's research. Alzheimer's disease sparks a cascade of changes throughout the body that lead to a slew of debilitating symptoms. But there's one surprising biological change that researchers are just starting to uncover, thanks to a new study. The study, which was published in the Journal of Lipid Research, found that people with Alzheimer's disease experience a breakdown in the ability to shuttle cholesterol to the neurons in their brain, and that this symptom is linked to a certain genetic variant called APOE4, which carries a known risk for Alzheimer's. This biological discovery could potentially pave the way for a better understanding of the disease and even future disease prevention methods. Here's what you need to know about the science so far, with input from a neurologist. Meet the expert: Clifford Segil, DO, is a neurologist at Providence Saint John's Health Center in Santa Monica, CA. What did the researchers find? For the study, researchers analyzed the cerebrospinal fluid (the biological liquid that surrounds and cushions the brain and spinal cord) from 10 patients with Alzheimer's disease and compared it to the cerebrospinal fluid of 10 people who did not have the condition. They discovered that lipoproteins (round particles made of fat and protein) in the cerebrospinal fluid of Alzheimer's patients were less effective at delivering cholesterol to neurons, or nerve cells, which are responsible for transmitting information from the brain throughout the body. What is cholesterol? Cholesterol is an essential, waxy, fat-like molecule that your body needs for good health, according to the National Heart Lung and Blood Institute (NHLBI). Cholesterol is carried around your body by two types of lipoproteins: low-density lipoproteins (a.k.a. LDL or 'bad' cholesterol) and high-density lipoproteins (a.k.a. HDL or 'good' cholesterol). High levels of LDL cholesterol can cause a buildup of fatty deposits called plaque in your arteries, raising the risk of heart attack, stroke, and other health complications, per the NHLBI. But high levels of good HDL cholesterol may lower the risk for certain health issues. Why is it important for brain function? While it has a bad rap in the health world, cholesterol is actually really important for your proper brain function. Your brain is the most cholesterol-rich organ in your body. Specifically, cholesterol helps make up cell membranes, including those in nerve cells, and plays a crucial role in your neurons' ability to "talk" to each other and transmit information. When cholesterol levels are out of balance, it can impact that transmission of essential information between nerve cells, leading to cognitive issues that are seen with neurodegenerative diseases like Alzheimer's disease. Cholesterol is also a building block for steroid hormones, which support brain function. However, that doesn't mean more cholesterol is always good for your brain. High levels of LDL cholesterol are usually considered a modifiable risk factor for ischemic stroke, or 'clogged pipes' in the brain, explains Clifford Segil, DO, a neurologist at Providence Saint John's Health Center in Santa Monica, CA. 'There is less research and understanding on the possible benefits of cholesterol found in spinal fluid including HDL, which we classically identify as the 'good cholesterol,'' Dr. Segil says. 'We know high levels of certain types of cholesterol cause strokes and we are less clear in the year 2025 about the benefits of cholesterol in brain function.' How does this link back to Alzheimer's? This particular study noted that cholesterol found in lipoproteins were different in patients with Alzheimer's disease, but Dr. Segil says that there is a 'complicated' relationship between lipids and protein in the brain. 'Some researchers continue to assign memory loss symptoms in patients with Alzheimer's due to abnormal brain protein levels and this paper noted lipid brain levels may also be abnormal,' he says. Dr. Segil points out that neurologists commonly prescribe medications called statins to lower levels of cholesterol and the risk of stroke. Lowering levels of LDL cholesterol can decrease the risk of developing certain type of dementia, including vascular dementia, he says. But it's not clear if it may do more. 'Further research will determine if lowering your cholesterol will result in lower chances of getting Alzheimer's dementia,' he says. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals Solve the daily Crossword
Yahoo
7 hours ago
- Yahoo
Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows
Anavex Life Sciences Corp. (NASDAQ:AVXL) reported a peer-reviewed publication in the journal Neuroscience Letters on Wednesday. The study shows that a pre-treatment with blarcamesine prevented Amyloid beta-induced memory impairment and brain oxidative injury. "This preclinical study is exciting since it clearly demonstrates a preventative effect of blarcamesine in Alzheimer's pathology and potentially might be able to prevent onset of Alzheimer's disease in healthy individuals," said Tangui Maurice, PhD, Research Director at the University of Montpellier, France and author of the placebo-controlled mice developed significant amyloid toxicity in the brains after the toxic Aβ25-35 peptide injection, in animals pre-treated with blarcamesine, significant protection was observed, with less vulnerability to Aβ25-35-induced oxidative stress and less vulnerability to develop learning and memory deficits. The mechanistic confirmation that blarcamesine particularly restores impaired autophagy through SIGMAR1 activation by acting upstream of amyloid and tau pathologies at the molecular level was previously established in vitro and in vivo. Blarcamesine studies demonstrated the effect of enhanced autophagic flux in human cells and in C. elegans, as well as increased proteostasis capacity and ability to promote autophagosome biogenesis, autophagic cargo reception, and lysosome fusion. SIGMAR1 has emerged as a key therapeutic target in the treatment of neurodegenerative disorders. Its activation enhances autophagy, facilitating the degradation of amyloid-beta precursor protein (APP) and helping to normalize Aβ production. SIGMAR1 activation supports neurogenesis, mitigates oxidative stress by reducing reactive oxygen species (ROS), suppresses neuroinflammatory responses, and alleviates Aβ-induced toxicity. It also plays a critical role in maintaining endoplasmic reticulum (ER) integrity and modulating intracellular calcium signaling. Collectively, these effects contribute to restoring cellular homeostasis, rebalancing neural function, and promoting neuroplasticity. In April, Anavex Life Sciences announced that over three years of continuous treatment with blarcamesine (ANAVEX 2-73) demonstrated significant amelioration of clinical decline, showing continued clinical and meaningful benefit for early Alzheimer's disease patients. Price Action: AVXL stock is up 1.59% at $9.59 during the premarket session at the last check on Wednesday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
Cheap supplement may protect against Alzheimer's in women
Omega fatty acids, found in certain fish or taken as a supplement, could potentially help ward off Alzheimer's disease in women, a new study suggests. Researchers found that lipids – fat molecules in the body – are different in women with Alzheimer's and those without. But they stressed that more work was needed to see whether 'shifting the lipid composition can influence the biological trajectory' of the disease. Scientists from Kings College London and Queen Mary University London, examined blood samples taken from 841 people, including 306 people with Alzheimer's; 165 with mild cognitive impairment and 370 healthy people. They discovered that there was a noticeable loss of unsaturated fats, including those that contain omega fatty acids, in the blood of women with Alzheimer's disease compared to healthy women, according to the study, which has been published in the journal Alzheimer's and Dementia: The Journal of the Alzheimer's Association. They also noted a steep increase in lipids with saturation – also known as 'unhealthy lipids' – in women with Alzheimer's compared to women without. But there was no difference between these fat molecules between men with, and without, a diagnosis of Alzheimer's – which researchers say could help deepen knowledge about why more women than men are diagnosed with Alzheimer's disease. 'Women are disproportionately impacted by Alzheimer's disease and are more often diagnosed with the disease than men after the age of 80,' said senior author of the study Dr Cristina Legido-Quigley, from King's College London. 'One of the most surprising things we saw when looking at the different sexes was that there was no difference in these lipids in healthy and cognitively impaired men, but for women this picture was completely different. 'The study reveals that Alzheimer's lipid biology is different between the sexes, opening new avenues for research. 'Our study suggests that women should make sure they are getting omega fatty acids in their diet – through fatty fish or via supplements. 'However, we need clinical trials to determine if shifting the lipid composition can influence the biological trajectory of Alzheimer's Disease.' Dr Asger Wretlind, first author of the study from King's College London, said: 'Although this still warrants further research, we were able to detect biological differences in lipids between the sexes in a large cohort, and show the importance of lipids containing omegas in the blood, which has not been done before. 'The results are very striking and now we are looking at how early in life this change occurs in women.' Dr Julia Dudley, head of research at Alzheimer's Research UK, which funded the study along with LundbeckFonden, said: 'In the UK, two in three people living with dementia are women. 'This could be linked to living longer, or other risk factors like social isolation, education, or hormonal changes from the menopause being at play. 'While this study shows that women with Alzheimer's had lower levels of some unsaturated fats compared with men, further work is needed. 'This includes understanding the mechanisms behind this difference and finding out if lifestyle changes, including diet could have a role.' People can consume omega-3 fatty acids by eating fatty fish including salmon, mackerel or sardines, or by taking a supplement. It comes as a separate study found that children who had a diet rich in omega-3 fatty acids may have a reduced risk of short sightedness. The study, published in the British Journal of Ophthalmology, examined data on 1,005 Chinese children aged between six and eight years, including their eye sight and regular surveys about their diet. Overall 28% of children had myopia. Researchers from Hong Kong found that a higher consumption of omega-3 fatty acids was associated with a lower risk of the condition.
